Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial

Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial

BackgroundTo investigate whether ivermectin inhibits SARS-CoV-2 proliferation in patients with mild-to-moderate COVID-19 using time to a negative COVID-19 reverse transcription-polymerase chain reaction (RT-PCR) test.MethodsCORVETTE-01 was a double-blind, randomized, placebo-controlled study (August...

Full description

Bibliographic Details
Main Authors: Tatsuhiko Wada, Makoto Hibino, Hiromi Aono, Shunsuke Kyoda, Yosuke Iwadate, Eri Shishido, Keisuke Ikeda, Nana Kinoshita, Yasuki Matsuda, Sakiko Otani, Ryo Kameda, Kenta Matoba, Miwa Nonaka, Mika Maeda, Yuji Kumagai, Junya Ako, Masayoshi Shichiri, Katsuhiko Naoki, Masato Katagiri, Masashi Takaso, Masatsugu Iwamura, Kazuhiko Katayama, Takeshi Miyatsuka, Yasushi Orihashi, Kunihiro Yamaoka, for the CORVETTE-01 Study Group
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Medicine
Subjects:
double-blind
ivermectin
SARS-CoV-2 proliferation
RT-PCR test
Japan
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1139046/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1139046/full

Similar Items